Dataset Information


Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension.

ABSTRACT: The main first-line treatment strategy for glaucoma is to reduce intraocular pressure (IOP) by topical ocular hypotensive medications, but many patients require multiple medications for adequate IOP control. Fixed-combination therapies provide several benefits, including simplified treatment regimens, theoretical improved treatment adherence, elimination of the potential for washout of the first drug by the second, and the reduction in ocular exposure to preservatives. ?-Adrenoceptor antagonists (particularly 0.5% timolol) are the most commonly used agents in combination with other classes of drugs as fixed-combination eyedrops, but they are contraindicated in many patients, owing to local allergy or systemic side effects. A fixed-combination preparation without a ?-blocker is therefore warranted. This paper reviews the clinical effectiveness of brinzolamide 1% and brimonidine 0.2% fixed combination (BBFC) for use in patients with primary open-angle glaucoma and ocular hypertension. We searched PubMed and the ClinicalTrials.gov registry, and identified three randomized controlled trials comparing BBFC vs its constituents (brimonidine vs brinzolamide), and one comparing BBFC with unfixed brimonidine and brinzolamide. All of the studies demonstrated mean diurnal IOP to be statistically significantly lower in the BBFC group compared with constituent groups and noninferior to that with the concomitant group using two separate bottles. The safety profile of BBFC was consistent with that of its individual components, the most common ocular adverse events being ocular hyperemia, visual disturbances, and ocular allergic reactions. Common systemic adverse effects included altered taste sensation, oral dryness, fatigue, somnolence, and decreased alertness. BBFC seems to be a promising new fixed combination for use in glaucoma patients. However, long-term effects of BBFC on IOP, treatment adherence, and safety need to be determined.


PROVIDER: S-EPMC4664487 | BioStudies | 2015-01-01T00:00:00Z


REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3709402 | BioStudies
1000-01-01 | S-EPMC3696917 | BioStudies
2014-01-01 | S-EPMC4271137 | BioStudies
2019-01-01 | S-EPMC6901046 | BioStudies
2020-01-01 | S-EPMC6986681 | BioStudies
2016-01-01 | S-EPMC5129854 | BioStudies
2019-01-01 | S-EPMC6603202 | BioStudies
2014-01-01 | S-EPMC4177101 | BioStudies
2008-01-01 | S-EPMC2694004 | BioStudies
2011-01-01 | S-EPMC3141858 | BioStudies